New combo therapy shows promise for tough pancreatic cancer
Disease control
Completed
This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine, in 36 people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could slow or stop cancer growth. Participants received …
Phase: PHASE2 • Sponsor: Susan E. Bates • Aim: Disease control
Last updated May 13, 2026 16:02 UTC